42C — IX Biopharma Income Statement
0.000.00%
- SG$17.76m
- SG$22.80m
- SG$7.77m
Annual income statement for IX Biopharma, fiscal year end - June 30th, SGD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.75 | 14.4 | 5.91 | 5.96 | 7.77 |
Cost of Revenue | |||||
Gross Profit | -0.382 | 12.3 | 2.32 | 1.05 | 2.04 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 9.98 | 18.5 | 15.6 | 15.9 | 17.9 |
Operating Profit | -8.23 | -4.1 | -9.71 | -9.98 | -10.1 |
Net Income Before Taxes | -8.23 | -4.1 | -9.71 | -9.98 | -10.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.23 | -4.6 | -9.62 | -10.8 | -10.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -8.23 | -4.6 | -9.62 | -10.8 | -10.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.23 | -4.6 | -9.62 | -10.8 | -10.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.012 | -0.006 | -0.012 | -0.014 | -0.012 |